Tag: EMPEROR-Reduced

Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status

Presented By
Prof. Faiez Zannad, University of Lorraine, France
Trial
EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney
Conference
HFA 2021
Type
Peer-reviewed article

19 August 2021 09:39

Empagliflozin significantly reduces CV and renal risk

Presented By
Dr Milton Packer, Baylor University Medical Center, Dallas, USA
Trial
EMPEROR-Reduced
Conference
EASD 2020
Type
News article

14 December 2020 12:40

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

Presented By
Dr Milton Packer, Baylor University Medical Center, USA
Trial
Phase 3, EMPEROR-Reduced trial
Conference
ESC 2020
Type
Peer-reviewed article

5 November 2020 13:40
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com